- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Visken
Synonyms :
pindolol
Class :
Intrinsic Sympathomimetic, Beta-Blockers
Dosage Forms & Strengths
Tablet
5mg
10mg
5
mg
Orally
twice a day; may increase up to 10 mg
3 - 4
week
(Off-label)
indicated for Chronic Stable Angina:
15 - 40
mg/day
Orally
dose divided every 4 hours
Safety & efficacy not established
Refer adult dosing
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
may increase the AV blocking effect of alpha2 agonists
it increases the effect of bradycardia of Beta-Blockers
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
may enhance the orthostatic hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may increase the effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
Beta-blockers increase the concentration of bupivacaine in the serum
Beta-Blockers decrease the efficacy of dobutamine
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may increase the bradycardic effect
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may decrease the bronchodilatory effect
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
Action and Spectrum:
pindolol has a short half-life, which means that it is quickly metabolized and eliminated from the body. This makes it a good option for patients who may not tolerate longer-acting beta-blockers. However, because of its non-selective action, pindolol may be less effective than more selective beta-blockers in certain situations, such as in the treatment of asthma or chronic obstructive pulmonary disease (COPD).
Overall, the spectrum of action for pindolol includes reducing heart rate, blood pressure, and cardiac output, which can be useful in the treatment of hypertension, angina, and some heart rhythm disorders. Its mild stimulatory effect on the heart may make it a good option for some patients who may not tolerate other beta-blockers. However, its non-selective action may limit its use in certain patient populations.
Frequency defined
1-10%
Dizziness (9%)
Muscle pain (10%)
Fatigue (8%)
Elevated liver enzymes (7%)
Insomnia (10%)
Nervousness (7%)
Joint pain (7%)
Vivid dreams (5%)
Edema (6%)
Abdominal discomfort (4-5%)
Muscle cramps (3%)
Nausea (4-5%)
Paresthesias (3%)
Cold extremities (2%)
Bradycardia (2%)
None
Contraindication / Caution:
pindolol is contraindicated in patients with:
pindolol should also be used with caution in patients with:
Pregnancy warnings:
Pregnancy category: B
Lactation: Excreted into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregna